Key Points {#FPar1}
==========

Implementation of pharmacogenomic testing in pediatric care is still scarce.To enable implementation of pharmacogenomic testing in clinical practice, consensus should be reached on the criteria that should be met before implementation.Heterogeneity of study populations is an important factor for impeding replication of pharmacogenomic associations.

Introduction {#Sec1}
============

Individuals with the same disease will often respond differently to the same drug. Some individuals will have a good response to the drug, while others experience little or no effect. Some patients will experience severe adverse drug reactions (ADRs), whereas others will not. In addition, some patients require a higher or lower dose compared with the standard dose defined in clinical trials to benefit optimally from the drug. In other words, personalizing drug treatment is required. Pharmacogenomics studies the relationship between genetic variation and drug responses. Single nucleotide polymorphisms (SNPs) can lead to changes in the function or the amount of proteins (e.g., enzymes, receptors, ion channels) and therefore in the drug response \[[@CR1]\]. Pharmacogenomics covers associations with both germline and somatic mutations. In this review only the influence of germline mutations will be discussed.

The first pharmacogenomic studies were designed as candidate gene studies. The candidate genes are selected based on potential involvement with drug response, such as genes coding for metabolic enzymes and drug target proteins. However, the cause of a different drug response is not always in the potentially involved genes, which makes it difficult to choose candidate genes.

The design of a genome-wide association study (GWAS) is more data driven than the hypothesis-driven candidate gene association studies. In a GWAS, the whole genome of participants is screened for all frequently occurring SNPs. With GWAS, besides SNPs in candidate genes, also previously unknown associations between a specific SNP and a certain response to a drug can be found. The newest innovations in pharmacogenomics, enabled by the rapid improvement of genomics technology, are phenome-wide association studies (PheWAS), whole exome sequencing (WES), and whole genome sequencing (WGS), which bring new opportunities to study the association between response and genetic variants \[[@CR2]\].

Most pharmacogenomic research has been performed in adults. However, it is important to realize that findings in the adult population cannot be applied directly to the pediatric population \[[@CR3]\]. Processes and systems (such as the metabolic system and hemostasis and drug biotransformation) are still under development in children \[[@CR3], [@CR4]\]. Therefore, drugs may act differently in children compared with adults. Although genetic variations remain stable, the contribution to treatment heterogeneity may be different at a younger age. In this article, we highlight examples of pharmacogenomic studies in pediatric patients. Pharmacogenomic research in childhood cancer is, apart from the focus on tumor genetics, focused on predicting which patients will suffer from severe ADRs. In the treatment of thrombosis, the studies have focused on predicting the right anticoagulant dose for each pediatric patient; and in asthma the main issue is to predict the efficacy of a bronchodilator drug. These are representative and extensively studied examples of the earlier mentioned sorts of differences in drug responses (ADRs, dose, and efficacy). These examples will give an insight into the challenges of pharmacogenomic research in children, but will also address the potential of pharmacogenomics to optimize and personalize treatment for children.

Pharmacogenomics in Children {#Sec2}
============================

Childhood Cancer {#Sec3}
----------------

In 2012, the worldwide estimated number of children under the age of 15 years diagnosed with cancer was 163,300 \[[@CR5]\]. The mean 5-year survival rates in the US are just above 80 %, but it largely depends on the type of cancer \[[@CR6]\]. With the increase in survival rates, the ADRs, which can cause lifelong damage, are becoming increasingly important during and after treatment. Anticancer drugs that are well known for their ADRs are cisplatin (ototoxicity, renal toxicity), anthracyclines (cardiotoxicity), and vincristine (neurotoxicity). These ADRs can have a large impact on quality of life. Many pharmacogenomic studies in the field of childhood cancer have focused on the toxicity of treatment. However, clinical implementation of pharmacogenomic testing is still pending in many centers because of inconclusive study results or uncertainty about whether and for which patients implementation is clinically relevant. We will discuss cisplatin as an example. This drug has been associated with a risk of ototoxicity, which can be very impairing, especially for children who are developing their speech skills \[[@CR7]\]. Several candidate gene studies have been conducted to investigate specific SNPs which are associated with an increased or decreased risk of ototoxicity. Variations in the following genes were found to influence the risk of cisplatin-induced ototoxicity: *TPMT*, *COMT*, *ABCC3*, *SOD2*, *GSTT1\*1*, *GSTP1*, *XPC*, *LRP2*, *Otos*, *SLC22A2*, *CTR1* and *GSTM3\*B* \[[@CR8]--[@CR18]\]. However, a major issue is the reproducibility of these initial findings. Several groups have conducted relatively small candidate gene studies on the association between ototoxicity and variations in *COMT* and *TPMT* in different cohorts \[[@CR9], [@CR19]--[@CR21]\]. The cohorts are very heterogeneous (Table [1](#Tab1){ref-type="table"}) and some lack statistical power. For *TPMT*, the association was replicated in two similar cohorts \[[@CR8], [@CR9]\]. One small Spanish cohort (*n* = 38) also showed an association for *TPMT*; however, because of the lack of power it was not statistically significant (rs12201199, odds ratio (OR) 6.79, 95 % confidence interval (CI) 0.34--13.71) \[[@CR20]\]. The association with *COMT* was replicated twice \[[@CR8], [@CR20]\], but in one of the studies the association was in the opposite direction \[[@CR20]\]. Another problem with *COMT* and *TPMT* is the lack of information on the mechanism in which these two enzymes are involved in cisplatin-induced ototoxicity.Table 1Overview of the characteristics of cisplatin-induced ototoxicity studiesRoss et al. \[[@CR8]\]Pussegoda et al. \[[@CR9]\]Yang et al. \[[@CR19]\]Lanvers-Kaminsky et al. \[[@CR21]\]Hagleitner et al. \[[@CR20]\]Xu et al. \[[@CR22]\]DiscoveryReplicationRadiationNo radiationSpanishDutchDiscoveryReplicationNumber of patients5310915521341633811023868Treatment protocolsNSNSNSSJMB-96; SJMB-03SJNB-97; SJNB-05; SJOS-08COSS-82/86/91; NB-90; MAHO-94; MAKEI-89; HIT-91NSNSSJMB-96; SJMB-03SJYC-07Age \[y\], median (range) Cases5 (0--16)6 (0--16)6 (1--25)7.6 (3.1--21.6)3--12 (0.8--18)11.8 (5--22)11.5 (4--29)15 (5--40)8.5 ± 3.8^b^\<5^c^ Controls9 (0--16)9.5 (1--19)11(0--18)10.1 (3.3--19.8)10 (2--13)13.9 (5--20)14 (7--28)15 (7--39.3)10.0 ± 4.3^b^Sex, male \[%\]67.957.849.766.270.760.355.350.062.2NSEthnicity \[%\]Caucasian 79.0^a^Caucasian 80.0White 78.9; non-white 21.1White 61.0; non-white 39.0NSEuropean ancestryDutch ancestryMixed populationNSCancer typeVarious cancersVarious cancersVarious cancersMedulloblastomaNeuroblastoma; osteosarcomaVarious cancers (mainly osteosarcoma)OsteosarcomaOsteosarcomaBrain tumorsBrain tumorsFollow up duration \[y\], median (range) or fixed number of yearsCases: 3 (0--18); controls: 2 (0--15)^a^Cases: 5 (0--25); controls: 2 (0--16)1.7NS2.5NS5.2 (0.06--21.3)2.12.1Craniospinal irradiation (%)17.019.318.11000NS00100NSConcurrent drug therapy Use of ototoxic antibioticsYesYesYesNSNSNSYesNoNSNS Vincristine (%)39.5^a^49.71000NS15.84.5100100Otoprotectants (%)NSNSNS90.60NS00\>870Cumulative cisplatin dose \[mg/m^2^\], median (range) Cases360 (180--630)400 (120--720)400 (92--800)300 (77--313)390--618 (113--1105)412 (120--644)504 (120--870)500 (100--600)287 ± 35^b^±300^c^ Controls360 (180--720)410 (100--700)400 (20--768)300 (79--312)254 (225--815)418 (161--560)515 (140--720)480 (200--600)289 ± 36^b^Ototoxicity grading scale and comparison groupsCTCAE \>1 vs CTCAE = 0CTCAE \>1 vs CTCAE = 0CTCAE \>0 vs CTCAE = 0 + ordinal and Chang score = 0 vs \>0; 2a vs ≥2a and ordinalCTCAE ordinalNSCTCAE \>1 vs CTCAE = 0; SIOP Boston ototoxicity scaleChang score \>0 vs Chang score = 0Outcome Association *COMT*YesYesNoNoNoNoYesNoNoNo Association *TPMT*YesYesYesNoNoNoNoNoNoNo*CTCAE* common terminology criteria for adverse events, *NS* not specified, *SIOP* international society of pediatric oncology, *y* years^a^Based on combined cohort (discovery + replication) \[[@CR9]\]^b^Mean and standard deviation given instead of median and range^c^Based on combined cohort (cases + controls)

Hagleitner et al. conducted a meta-analysis for *COMT* and *TPMT* in 2014 and found only a small association for *COMT* (rs4646316) (OR 1.52, 95 % CI 1.16--1.99, *p* = 0.003). For the analyzed *TPMT* mutations there was a trend towards increased risk (rs12201199; OR 2.15, 95 % CI 1.16--1.99, *p* = 0.003) \[[@CR20]\]. However, it is debatable if these results give an accurate effect estimation, because of the heterogeneity in populations of the included studies.

Recently, a GWAS failed to find any association for *TPMT*, *COMT* or any of the other genes studied in the candidate gene studies \[[@CR22]\]. The GWAS study was conducted in 238 pediatric patients with newly diagnosed brain tumors. A strong association was found for a mutation in *ACYP2* (rs1872328, hazard ratio 4.5, 95 % CI 2.63--7.69, *p* = 3.9 × 10^−8^), which was replicated in a new cohort of 68 patients that was almost similarly treated as the discovery cohort. In the discovery and the replication cohorts, 100 % of the patients that carried at least one mutated allele developed ototoxicity. In the patients with no mutated allele, still more than 70 % developed ototoxicity \[[@CR22]\].

*ACYP2* encodes for an acylphosphatase which is, among other places, expressed in the cochlea \[[@CR23]\]. The exact mechanism by which this mutation in *ACYP2* increases the risk of ototoxicity is still unclear.

The problems with replication of the results found in the different candidate studies has led to an extensive discussion about the underlying reasons \[[@CR24]--[@CR28]\]. The replication issues could be largely due to small sample sizes and differences in the study populations (age, ethnicity, and type of cancer), scoring of ototoxicity, length of follow-up, cumulative dose of cisplatin, and concurrent drug treatment (e.g., use of otoprotectants and craniospinal irradiation) (Table [1](#Tab1){ref-type="table"}). Heterogeneity also existed within the studies, like different treatment regimens and types of cancer. The heterogeneities complicate replicating the results and it is uncertain if the associations found are true or only a result of confounding or bias. At present, only *TPMT* is mentioned in the label information of cisplatin as a possible contributor to ototoxicity, but no clinical recommendations are provided \[[@CR29]\].

From these studies we can conclude that the mutation in *ACYP2* seems to be an important predictor of ototoxicity in children, but that it explains only a small part (12.4 %) of ototoxicity \[[@CR22]\]. More research is needed to replicate these findings, and to find practical solutions for the implementation of *ACYP2* testing in clinical practice. Studies of the mechanism for *TPMT* and *COMT* involvement in cisplatin-induced ototoxicity and independent replication in similar cohorts are required.

For some patients the toxicity is unacceptable (e.g., ototoxicity for a patient who is blind). In such patients, decisions on therapy will be influenced by genetic polymorphisms that enhance the risk of developing toxicity. With the identification of significant risk variants, patients who are at an increased risk can be identified and might be given alternative treatments and/or undergo closer monitoring during treatment and the follow-up period. Adapting complex treatment regimens in an attempt to reduce side effects is complicated since efficacy must remain intact. Different approaches maybe explored: identifying a protecting agent against ototoxicity is an attractive option. The knowledge gained from the identification of variants that influence the risk of cisplatin-induced ototoxicity can be used to identify new drug targets for protecting agents. This research is promising and will eventually lead to a more personalized anticancer treatment.

Thrombosis {#Sec4}
----------

In recent years there has been a higher incidence of thrombosis in children \[[@CR30]\], mainly due to intensified medical treatments and increased awareness of the risk of thrombosis. Currently, low molecular weight heparins (LMWHs) and vitamin K antagonists (VKAs) are the only two drugs approved for the treatment or prevention of thrombosis in pediatric patients. The relatively new direct oral anticoagulants (DOACs) are currently being tested in pediatric patients. In 2018, the first phase III studies with DOACs in pediatric patients will be completed. At this time, the VKAs are the only oral drugs which are approved for the treatment of thrombosis in pediatric patients.

VKAs inhibit the action of vitamin K epoxide reductase (VKORC1), which leads to lower levels of active vitamin K-dependent clotting factors, and thus to inhibition of the coagulation cascade \[[@CR31]\]. In clinical practice, a large variability in dose requirement of VKAs is seen \[[@CR32]\]. This is problematic because VKAs also have a narrow therapeutic window. Dosing all patients equally leads to an increased risk of bleeding and thrombotic events. In children, this problem is even more compelling because of the developing hemostatic system and the growing body. In the last decade, many studies have been carried out to explain the large interindividual dose variability in children and adults \[[@CR33], [@CR34]\]. In addition to clinical factors such as age, weight, and gender, genetic factors play an important role \[[@CR34]\]. Mutations in *VKORC1* lead to less enzyme production and to a lower dose requirement. Loss-of-function mutations in *CYP2C9* (\*2 and \*3) lead to a decrease in the enzyme activity. The S-isomer of VKAs is almost completely metabolized by CYP2C9; therefore, the mutation leads to a decrease in the required dose \[[@CR31], [@CR35]\]. To a lesser extent, mutations in *CYP4F2* and *CYP2C18* have also been found to be (possibly) contributing to the dose variability \[[@CR33], [@CR35]--[@CR37]\].

Seven regression dosing models have been constructed for pediatric patients, almost all for warfarin \[[@CR38]--[@CR44]\]. No pediatric dosing model is available for acenocoumarol. What these pediatric models have in common is that factors related to ontogeny (i.e., age, weight, and height) explain roughly one-third of the dosing variability. The variability explained by the *CYP2C9* and *VKORC1* genotypes fluctuates between the different models. The *CYP2C9* genotype explained 0.4 \[[@CR38]\] to 12.8 % \[[@CR39]\] of the variability in dose requirement, the *VKORC1* genotype 3.7 \[[@CR38]\] to 47 % \[[@CR41]\]. One of the possible explanations is the small sample size of the cohorts ranging from 37 to 120 children. Only two studies included at least 100 patients \[[@CR39], [@CR44]\].

Also, two pharmacokinetic/pharmacodynamic (PK/PD) dosing models have been built for pediatric patients \[[@CR45], [@CR46]\]. Hamberg and Wadelius evaluated the regression and PK/PD models in a retrospective pediatric cohort \[[@CR34]\]. Of the evaluated models, the PK/PD model of Hamberg et al. \[[@CR46]\] performed best with regards to the proportion of patients for whom the predicted maintenance dose was within ±20 % of the observed dose. Hamberg et al. developed a tool for their model which can run on every computer without licensing for a program and is easy to use \[[@CR47]\]. The best performing regression model incorporates the *CYP2C9* and *VKORC1* genotype, height, and indication and can be used with a simple pocket calculator \[[@CR39]\].

Until now, no randomized controlled trial (RCT) has been conducted with a regression dosing model in children. One trial has just started, in which a PK/PD dosing model is tested against standard dosing \[[@CR48]\]. In adults, 12 RCTs have been carried out to evaluate the dosing algorithms \[[@CR49]\]. These trials gave conflicting results with regards to improving the time within therapeutic range (TTR) and outcomes such as bleeding and thromboembolic complications. In a recent meta-analysis, a statistically significant increase in TTR and decrease in minor bleeding was found when comparing fixed standard dosing with genotype-guided dosing \[[@CR49]\].

Currently, the American College of Chest Physicians (ACCP) guideline for antithrombotic therapy and prevention of thrombosis does not recommend genotyping before starting VKAs in adults \[[@CR50]\]. The FDA follows this recommendation, while still including information on the impact of pharmacogenomics in the drug label \[[@CR51]\]. When genetic information is available, the physician can use this to adjust the dose. In pediatric patients, this information should not be used. Studies showed that the adult models overestimate the VKA dose in children \[[@CR39], [@CR42]\]. Therefore, pediatric models should be used when genetic information is available. An RCT for examining a pediatric regression model does not seem to be a realistic option for determining the usefulness of genotyping before starting a VKA. The numbers of children using these drugs are very low, and therefore such a trial would be very costly and time consuming. We think the pediatric algorithms should be implemented and evaluated in a clinical setting. Using a dosing model can only lead to an increase in the quality of treatment. There are no risks involved, because adjustments of the dose can still be made based on the International Normalized Ratio (INR). The costs of using a model only consist of the price of genetic testing and these costs are already quite reasonable compared with other medical tests, and will probably decrease further over time. It might be possible that genotyping becomes cost effective, because when INR stability increases it is likely that fewer INR measurements will be needed, and fewer bleeding and thrombotic events will occur. Evaluations should be carried out during implementation in order to determine if the genetic testing is increasing the quality of treatment and/or lowering the costs.

Asthma {#Sec5}
------

Asthma is the most common chronic disease in children. Asthma is treated with a stepwise approach \[[@CR52]\]. Short-acting β2 agonists (SABA) as needed are prescribed initially to relieve symptoms of bronchoconstriction. Inhaled corticosteroids (ICS) are added to the regimen if asthma symptoms persist to reduce the airway inflammation and are considered to be the cornerstone of asthma treatment \[[@CR52]\]. Additionally, long-acting β2 agonists (LABA) or leukotriene receptor agonists (LTRA) can be added if a child's asthma remains insufficiently controlled. Although asthma treatment is effective in many patients, there is a large variability in the level of symptom control or lung function improvement. Already more than 15 years ago, Drazen et al. suggested that up to 80 % of the interindividual variants in drug response in asthmatic patients could be due to genetic variations \[[@CR53]\]. Since then, candidate gene approaches and a handful of GWAS studies have described several genetic variants associated with asthma treatment response, yet effect sizes are often small and a successful replication remains rare \[[@CR54]--[@CR56]\].

Pharmacogenomics of LABA seems closest to clinical implementation. An SNP of interest (*ADRB2* Arg16) has been replicated and prospectively tested and the risk genotype is relatively frequent within the population. Variation in the gene that encodes the β2 receptor (ADRB2) is associated with LABA response in children \[[@CR57]--[@CR59]\], yet not all studies point in the same direction \[[@CR60]\]. Nevertheless, a recent meta-analysis of 4226 children of white Northern European and Latino origin showed that this variant (*ADRB2* Arg16) was associated with an increased risk of asthma exacerbation when treated with ICS + LABA (OR 1.52, 95 % CI 1.17--1.99; *p* = 0.0021) \[[@CR61]\]. In addition, further evidence has been provided by a small prospective study of 62 children with the genetic variation randomized to ICS + LABA or ICS + LTRA. The trial showed that children treated in the ICS + LTRA arm had fewer exacerbations (exacerbation score of −0.39, 95 % CI −0.15 to −0.64; *p* = 0.049) and school absences (difference in scores of 0.40, 95 % CI −0.22 to −0.58; *p* = 0.005) compared with the group treated with ICS + LABA \[[@CR62]\]. Approximately 16 % of the children with asthma are homozygous for this variant \[[@CR57]\], and may benefit from genotyping before initiation of LABA treatment. Larger trials are necessary to assess the clinical value and cost effectiveness of *ADRB2* genotyping.

Defining treatment response in asthma is complicated. Symptoms vary over time and different dimensions of response (lung function, exacerbations, and symptoms) can be associated with different genetic risk profiles \[[@CR63]\]. Furthermore, asthma consists of a heterogeneous population of various distinct phenotypes (e.g., eosinophilic versus neutrophilic asthma), which seems to differ for children and adults. Performing studies in children is therefore of the uttermost importance. Recently, the Pharmacogenomics in Childhood Asthma (PiCA) consortium has been formed to bring asthma researchers in this field together to perform meta-analyses in well defined joined pediatric asthma cohorts \[[@CR61], [@CR64]\].

Challenges and Future Directions {#Sec6}
================================

Although the research field of pediatric pharmacogenomics is rapidly growing, few applications have made it to clinical practice. We have provided examples of three pediatric diseases where pharmacogenomics holds a promise to personalize treatment: childhood cancer, thrombosis, and asthma. These examples illustrate that gathering evidence for a pharmacogenomic association in children is challenging. Replication of genetic associations is complicated by the heterogeneity in both outcome measures and in small study populations in terms of ethnicity, disease phenotype, and age, which leads to underpowered biased studies. To overcome this obstacle, collaborations should be undertaken to enlarge the number of patients studied.

More studies have been performed on pharmacogenomic associations in adults, including a couple of RCTs, but unfortunately these results in adults cannot be simply extrapolated to children. Pharmacogenomic studies in pediatric populations remain essential. The therapeutic goal of a certain treatment is often different for adults and children. In addition, differences in co-medication, diet, and duration of drug use can also lead to dissimilar results. Before data can be extrapolated to children it should be clear if the association is not influenced by ontogeny. Children not only differ from adults in body size, but also in the dynamic expression of metabolic enzymes, drug transporters, and drug targets \[[@CR3], [@CR65]\]. Furthermore, the organs involved in drug metabolism and elimination (liver and kidney) are under the influence of developmental processes during childhood \[[@CR3]\]. Besides these physical differences, the disease can also manifest itself differently in children, as seen, for example, in asthma \[[@CR66]\]. These differences make it hard to predict the PK/PD of a drug in children. The drug response can differ between children, but also within one child over time. Therefore, the extrapolation of results between children of different ages should be done with the same caution as the extrapolation of adult data to children. Pediatric patients span a period from birth to adulthood by most definitions. An RCT is still considered the gold standard to collect evidence. However, performing RCTs in children is complicated by the large sample sizes which are required, especially in rare diseases such as cancer and thrombosis. For example, in the case of VKAs, obtaining the required sample size is a large problem. For the EU-PACT (European Pharmacogenetics of Anticoagulant Therapy) trial in adults, investigating the effectiveness of the pharmacogenomic dosing models for acenocoumarol, phenprocoumon, and warfarin, the calculated sample size was 400 per VKA \[[@CR67], [@CR68]\]. To put this in perspective, in the Netherlands, currently only 226 children under the age of 15 years use VKAs \[[@CR69]\]. To obtain the number of patients needed, international collaborations are essential. Besides the large sample size, the high costs of an RCT need to be considered. This type of research is usually not in the direct interest of pharmaceutical companies, especially if it concerns off-patent drugs. Therefore, it is difficult to find funding for these kinds of trials, and specific financial or other incentives might be required to bridge this obstacle \[[@CR70]\].

As stated in the introduction, the improvement of genomics technology creates opportunities to study pharmacogenomics in new ways. The newest is PheWAS, which is the opposite of GWAS. Instead of studying genetic associations with a predefined phenotype, patients with a certain mutation are the starting point to search for the matching phenotype. Other examples are WES/WGS in which all DNA mutations will be considered, in contrast to GWAS, which is directed to known (frequently occurring) SNPs.

There is no one method better than the others. Which method or combination of methods is the most appropriate depends largely on the research question/situation (e.g., knowledge about drug mechanism, available budget). Findings of a GWAS, for instance, can be subsequently replicated in a candidate gene study, which requires far fewer patients and is less expensive than an additional GWAS.

The progression from gathering evidence to clinical relevance is not easy. Even when an association is strong it does not mean that it is clinically relevant. For example, in the case of *ACYP2* and ototoxicity, the association was quite strong, but it still could explain only 12.4 % of the ototoxicity cases. The clinical relevance largely depends on the relative frequency of the risk allele in the population of interest, the disease phenotype, the severity of the outcome, and the risk attribution of the risk-allele to the outcome. Cost effectiveness of a pharmacogenomic test is inevitably necessary to reach clinical implementation. Even when the costs of genetic testing decline, other costs such as the costs of the possible alternative treatment, use of protective agents, and/or extra monitoring should be considered.

To be able to proceed with implementation of pharmacogenomic testing in children, consensus should be reached about what evidence is needed to implement a pharmacogenetic test into clinical practice if RCTs are not feasible. Furthermore, in some cases performing an RCT could be considered unethical. An important example of this is the risk of codeine-induced infant mortality based on a *CYP2D6* genotype of breastfeeding mothers \[[@CR71]\]. This has led to a change in the registration of codeine. Codeine is no longer approved for pediatric use in the EU and is contraindicated in women during breastfeeding \[[@CR72]\].

When an RCT is impossible, at least worldwide replication studies are needed to support the generalizability of the association. This is only possible with international collaboration. However, the healthcare systems and availability of treatment options (e.g., differences in authorized VKAs) differ largely between countries and treatment protocols vary between countries, study populations, and over time. This makes finding a comparable replication cohort challenging. Therefore, international treatment harmonization would ease the process of worldwide replication studies.

Strong evidence in adults might support the associations found in pediatric patients. However, because of differences related to ontogeny, adult-derived information should be considered with caution and is not essential. This caution should also be applied when using the dosing guidelines available for adults. As seen in the example for VKAs, using the adult models would lead to an overestimation of the required dose. Pharmacogenomics needs to be considered as valuable information in addition to clinical parameters to guide treatment decisions.

It is important that consensus is reached about the evidence needed for implementation and that healthcare professionals also support these criteria; published, peer-reviewed clinical practice guidelines could be of particular help here. Clinicians need to be appropriately educated on the value of pharmacogenomic testing. Only then will pharmacogenomics be implemented in pediatric clinical practice.

Conclusion {#Sec7}
==========

Pharmacogenomics is a promising research field, but has not reached the pediatric clinic yet. International collaborations are needed to gain a more structured approach for pharmacogenomic research in children. When heterogeneity is reduced and research groups work together in order to obtain larger numbers of patients, it is possible to get stronger evidence, both qualitatively and quantitatively. The criteria for implementing a pharmacogenomic test without the presence of a supporting pediatric RCT should be further elaborated by healthcare professionals and researchers. Reaching consensus could lead to easier acceptance by healthcare professionals to the use of these tests in daily clinical practice.
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